Olaparib (also called Lynparza) is part of a drug class called PARP inhibitors and is currently approved for the treatment of certain ovarian and breast cancers. PARP inhibitors work by exploiting a certain type of defect that some cancers have in their DNA repair mechanisms and are currently under ...

Asbestos is associated with more than 80% of cases of mesothelioma – a rare cancer that develops on the thin layer of tissue that covers internal organs. In collaboration with the Mesothelioma Cancer Alliance we explore this rare form of the disease and how research into this cancer is vital for i...

Our charity prides itself on funding stellar research from all over the world, which means we're in touch with a worldwide community of people who encounter cancer in different ways: researchers, patients, friends and family members. Recently, we became aware of 3 inspirational women in Beirut, when...